Wall St. provides estimates for future stock prices of Eli Lilly from 2026 to 2030 based on projected revenue and net income.

Eli Lilly leads the weight loss market ahead of Novo Nordisk. Eli Lilly also has a more diversified lineup of products than ...

Although the stock is trading at a premium valuation, the company’s outstanding operational performance, strong financial ...

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 4.5% in the afternoon session after the U.S.

Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game.

Eli Lilly And Co (NYSE:LLY) and Novo Nordisk (NYSE:NVO), are reportedly being sued in Texas by compounding pharmacy Strive ...

Eli Lilly is riding the wave of a booming weight management market. Eli Lilly's tirzepatide, sold under the brand names ...

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The company still has a robust business that is delivering excellent results and ...

Eli Lilly and Company rated Buy: incretin/obesity growth, ZEPBOUND & orforglipron access strategy, pipeline deals, ...

Eli Lilly (LLY) downgraded to Sell as obesity-drug competition and pricing pressure rise; stretched valuation boosts downside ...

Eli Lilly stock has soared in the triple digits over three years. Investors are excited about the company’s portfolio of weight loss drugs, which has generated blockbuster revenue. Investors generally ...